Gabriella Zupi

Gabriella Zupi

Auto-generated profile, based on publicly available information

Gabriella Zupi

Experimental Chemotherapy Laboratory, Regina Elena Cancer Institute, Rome, Italy

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2001 in The American Journal of Pathology
Verified
Journal Article
Open access
PDF file
ABAnnamaria Biroccio
Annamaria Biroccio
BBBarbara Benassi
Barbara Benassi
Igea D'AgnanoIgea D'Agnano
Igea D'Agnano
CDCarmen D’angelo
Carmen D’angelo
SBSimonetta Buglioni
Simonetta Buglioni
GZGabriella Zupi
Gabriella Zupi
The aim of this study was twofold: to assess the relationship between c-Myb and Bcl-x expression and to evaluate the prognostic significance of their expression in colorectal carcinoma (CRC) patients. Analysis of tumors from 91 CRC patients for expression of c-Myb and Bcl-x revealed a significant relationship between these two proteins. Kaplan-Meier’s analysis showed an increased risk of relapse and death in patients whose tumor specimens displayed high c-Myb levels and Bcl-x positivity. Similar results were also observed excluding Dukes’ D patients. Molecular analysis using three c-Myb-overexpressing LoVo clones indicated that c-Myb overexpression was accompanied by up-regulation of Bcl-xL protein and mRNA. Tumors originating from these clones injected in nude mice were significantly larger than those formed in mice injected with parental or vector-transfected LoVo cells. Moreover, tumors derived from parental and control vector-transfected but not from c-Myb-overexpressing LoVo cells showed high frequency of apoptotic cells. These results provide direct evidence of an association between c-Myb and Bcl-x expression and suggest that expression of both molecules might be a useful prognostic marker in CRC.

29 September 2003 in Oncogene
Verified
Journal Article
Closed access
ABAnnamaria Biroccio
Annamaria Biroccio
CLCarlo Leonetti
Carlo Leonetti
GZGabriella Zupi
Gabriella Zupi


28 August 2006 in Oncogene
Verified
Journal Article
Closed access
CGChiara Gabellini
Chiara Gabellini
Donatella Del BufaloDonatella Del Bufalo
Donatella Del Bufalo
GZG Zupi
G Zupi

20 November 2003 in Oncogene
Verified
Journal Article
Closed access
Donatella Del BufaloDonatella Del Bufalo
Donatella Del Bufalo
Daniela TrisciuoglioDaniela Trisciuoglio
Daniela Trisciuoglio
MSMarco Scarsella
Marco Scarsella
UZUwe Zangemeister-Wittke
Uwe Zangemeister-Wittke
GZGabriella Zupi
Gabriella Zupi

3 February 2005 in Journal of Translational Medicine
Verified
Journal Article
Open access
ATAnna Tesei
Anna Tesei
Paola UliviPaola Ulivi
Paola Ulivi
FFFrancesco Fabbri
Francesco Fabbri
MRMarco Rosetti
Marco Rosetti
CLCarlo Leonetti
Carlo Leonetti
WZWainer Zoli
Wainer Zoli
Background: Nitric oxide-releasing nonsteroidal antiinflammatory drugs (NO-NSAIDs) are reported to be safer than NSAIDs because of their lower gastric toxicity. We compared the effect of a novel NO-releasing derivate, NCX 4040, with that of aspirin and its denitrated analog, NCX 4042, in in vitro and in vivo human colon cancer models and investigated the mechanisms of action underlying its antitumor activity. Methods: In vitro cytotoxicity was evaluated on a panel of colon cancer lines (LoVo, LoVo Dx, WiDr and LRWZ) by sulforhodamine B assay. Cell cycle perturbations and apoptosis were evaluated by flow cytometry. Protein expression was detected by Western blot. In the in vivo experiments, tumor-bearing mice were treated with NCX 4040, five times a week, for six consecutive weeks. Results: In the in vitro studies, aspirin and NCX 4042 did not induce an effect on any of the cell lines, whereas NCX 4040 produced a marked cytostatic dose-related effect, indicating a pivotal role of the -NO2 group. Furthermore, in LoVo and LRWZ cell lines, we observed caspase-9 and -3-mediated apoptosis, whereas no apoptotic effect was observed after drug exposure in WiDr or LoVo Dx cell lines. In in vivo studies, both NCX 4040 and its parental compound were administered per os. NCX 4040 induced a 40% reduction in tumor weight. Conversely, aspirin did not influence tumor growth at all. Conclusions: NCX 4040, but not its parental compound, aspirin, showed an in vitro and in vivo antiproliferative activity, indicating its potential usefulness to treat colon cancer.